| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,840 |
9,482 |
$928K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,880 |
9,969 |
$901K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,270 |
4,388 |
$454K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,335 |
2,178 |
$205K |
| 36415 |
Collection of venous blood by venipuncture |
11,580 |
8,515 |
$190K |
| 80053 |
Comprehensive metabolic panel |
13,592 |
10,895 |
$117K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,587 |
1,421 |
$86K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,070 |
1,729 |
$74K |
| 87430 |
|
849 |
796 |
$49K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
739 |
645 |
$48K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,232 |
1,108 |
$43K |
| 87400 |
|
1,311 |
1,166 |
$38K |
| 81001 |
|
6,822 |
5,891 |
$32K |
| 81003 |
|
1,878 |
1,661 |
$31K |
| 87088 |
|
3,039 |
2,620 |
$28K |
| 71045 |
Radiologic examination, chest; single view |
4,722 |
4,008 |
$24K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,202 |
2,644 |
$24K |
| 59025 |
Fetal non-stress test |
721 |
462 |
$23K |
| 84484 |
|
3,171 |
2,387 |
$20K |
| 86900 |
|
600 |
516 |
$20K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,072 |
769 |
$17K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
623 |
560 |
$16K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,399 |
1,092 |
$16K |
| 85610 |
|
1,853 |
1,448 |
$15K |
| A9270 |
Non-covered item or service |
12,318 |
6,621 |
$14K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
137 |
116 |
$14K |
| 85027 |
|
2,206 |
1,791 |
$13K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
12,693 |
10,052 |
$13K |
| J2704 |
Injection, propofol, 10 mg |
1,122 |
908 |
$13K |
| 85730 |
|
1,318 |
1,094 |
$12K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
529 |
428 |
$11K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
129 |
40 |
$11K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,110 |
967 |
$11K |
| 86901 |
|
602 |
515 |
$11K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
994 |
742 |
$10K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,382 |
3,567 |
$9K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
155 |
147 |
$7K |
| 81025 |
|
2,658 |
2,432 |
$7K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,412 |
1,325 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
657 |
588 |
$7K |
| 99218 |
|
310 |
158 |
$6K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,871 |
1,406 |
$6K |
| 87486 |
|
1,237 |
1,162 |
$5K |
| 99215 |
Prolong outpt/office vis |
434 |
271 |
$5K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,366 |
2,090 |
$5K |
| 93041 |
|
1,979 |
1,700 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,126 |
1,615 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
98 |
93 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
29 |
29 |
$3K |
| 73610 |
|
55 |
52 |
$3K |
| 83690 |
|
2,833 |
2,397 |
$3K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,903 |
1,623 |
$3K |
| 93975 |
|
164 |
152 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
121 |
111 |
$3K |
| 80061 |
Lipid panel |
1,607 |
1,367 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,290 |
911 |
$2K |
| 73562 |
|
50 |
41 |
$2K |
| 84702 |
|
580 |
484 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
224 |
194 |
$2K |
| 94760 |
|
575 |
406 |
$2K |
| 86850 |
|
101 |
81 |
$1K |
| 87081 |
|
977 |
925 |
$1K |
| 83735 |
|
1,646 |
1,228 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
354 |
332 |
$1K |
| 87040 |
|
611 |
419 |
$1K |
| 87210 |
|
125 |
117 |
$988.30 |
| 76801 |
|
62 |
57 |
$951.42 |
| 87631 |
|
14 |
12 |
$869.09 |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
73 |
66 |
$864.19 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
359 |
339 |
$863.18 |
| 87077 |
|
60 |
52 |
$852.71 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
73 |
65 |
$836.07 |
| 94664 |
|
906 |
674 |
$811.18 |
| 82947 |
|
18 |
13 |
$789.20 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
471 |
396 |
$771.53 |
| 83880 |
|
561 |
480 |
$578.09 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
286 |
244 |
$533.51 |
| 83605 |
|
533 |
443 |
$503.39 |
| 87420 |
|
289 |
282 |
$485.19 |
| 87186 |
|
1,039 |
883 |
$411.97 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
244 |
190 |
$352.65 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
131 |
115 |
$307.01 |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
12 |
12 |
$302.41 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,383 |
2,079 |
$286.60 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
253 |
196 |
$242.78 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
33 |
29 |
$234.52 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
22 |
21 |
$212.25 |
| 76830 |
Ultrasound, transvaginal |
14 |
12 |
$209.06 |
| 84703 |
|
765 |
698 |
$204.59 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
896 |
827 |
$191.90 |
| 82077 |
|
204 |
181 |
$177.98 |
| 73630 |
|
74 |
58 |
$174.37 |
| 93971 |
|
41 |
36 |
$141.37 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,237 |
1,162 |
$112.51 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
372 |
312 |
$108.68 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
57 |
50 |
$102.38 |
| 86140 |
|
61 |
51 |
$101.43 |
| 82607 |
|
110 |
91 |
$79.91 |
| J2060 |
Injection, lorazepam, 2 mg |
232 |
182 |
$78.93 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
15 |
14 |
$67.91 |
| 85379 |
|
113 |
96 |
$67.74 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
29 |
24 |
$45.78 |
| 87581 |
|
1,237 |
1,162 |
$40.33 |
| 82043 |
|
17 |
13 |
$39.68 |
| J1790 |
Injection, droperidol, up to 5 mg |
30 |
29 |
$33.44 |
| 96376 |
|
162 |
88 |
$32.48 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
997 |
845 |
$7.87 |
| 86308 |
|
14 |
14 |
$6.05 |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
15 |
13 |
$6.03 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
87 |
67 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
52 |
26 |
$0.00 |
| 85007 |
|
16 |
16 |
$0.00 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
13 |
12 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
19 |
12 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
24 |
13 |
$0.00 |
| 82550 |
|
13 |
12 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
79 |
66 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
88 |
84 |
$0.00 |
| G0378 |
Hospital observation service, per hour |
33 |
25 |
$0.00 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
13 |
12 |
$0.00 |